Cover Image
市場調查報告書

抗藥性金黃色葡萄球菌 (MRSA) - 現在、未來的企業

Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players

出版商 GlobalData 商品編碼 365838
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
抗藥性金黃色葡萄球菌 (MRSA) - 現在、未來的企業 Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players
出版日期: 2015年12月16日 內容資訊: 英文 125 Pages
簡介

本報告提供抗藥性金黃色葡萄球菌 (MRSA) 治療藥市場相關調查分析,以急速成長中的市場形成的主要企業為焦點,包含新興企業的競爭情形相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素、障礙 - 全球問題點

第4章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介 - 目前企業
    • Pfizer
    • Merck
    • Allergan
    • The Medicines Company
    • Theravance Biopharma
    • Basilea Pharmaceutica
    • Sanofi
  • 擁有有前途的開發中產品的新興企業
    • Melinta Therapeutics
    • Cempra Pharmaceuticals
    • Paratek Pharmaceuticals
    • 杏林藥業
    • Nabriva Therapeutics
    • Debiopharm International
    • Cellceutix Corporation

第5章 附錄

圖表

目錄
Product Code: GDHC1046FPR

GlobalData has released its pharma report, "Methicillin-Resistant Staphylococcus aureus (MRSA) - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MRSA Market. The report identifies and analyses the key companies shaping and driving the global MRSA market. The report provides insight into the competitive MRSA landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for MRSA
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of MRSA sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving MRSA market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global MRSA market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers. Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles. Current Players
    • 4.3.1. Pfizer
    • 4.3.2. Merck
    • 4.3.3. Allergan
    • 4.3.4. The Medicines Company
    • 4.3.5. Theravance Biopharma
    • 4.3.6. Basilea Pharmaceutica
    • 4.3.7. Sanofi
  • 4.4. Additional Companies with Promising Pipeline Products
    • 4.4.1. Melinta Therapeutics
    • 4.4.2. Cempra Pharmaceuticals
    • 4.4.3. Paratek Pharmaceuticals
    • 4.4.4. Kyorin Pharmaceutical
    • 4.4.5. Nabriva Therapeutics
    • 4.4.6. Debiopharm International
    • 4.4.7. Cellceutix Corporation

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Hospitalized MRSA Patients
    • 5.4.2. Percentage of Drug-Treated MRSA Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch, Label Expansion, and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
    • 5.4.8. Pricing of Pipeline Agents
  • 5.5. Primary Research. KOLs Interviewed for This Report
  • 5.6. Primary Research. Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Author and Therapy Area Director
    • 5.7.2. Author
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Director of Therapy Analysis and Epidemiology
    • 5.7.5. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for MRSA Therapeutics, 2014-2024
  • Table 2: MRSA Therapeutics Market - Global Drivers and Barriers, 2014-2024
  • Table 3: Key Companies in the MRSA Marketplace in the 7MM, 2015
  • Table 4: Pfizer's MRSA Portfolio Assessment, 2015
  • Table 5: Merck's MRSA Portfolio Assessment, 2015
  • Table 6: Allergan's MRSA Portfolio Assessment, 2015
  • Table 7: The Medicines Company's MRSA Portfolio Assessment, 2015
  • Table 8: Theravance Biopharma's MRSA Portfolio Assessment, 2015
  • Table 9: Basilea Pharmaceutica's MRSA Portfolio Assessment, 2015
  • Table 10: Sanofi's MRSA Portfolio Assessment, 2015
  • Table 11: Companies with Promising Pipeline Candidates for MRSA in the 7MM, 2015
  • Table 12: Key Historical and Projected Launch Dates for MRSA Across the 7MM
  • Table 13: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
  • Table 14: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for MRSA Therapeutics by Country, 2014 and 2024
  • Figure 2: Global Sales for MRSA Therapeutics by Region, 2014-2024
  • Figure 3: Global Sales for MRSA Therapeutics by Drug Class, 2014 and 2024
  • Figure 4: Global Sales for MRSA Therapeutics by Infection Site, 2014-2024
  • Figure 5: Global Sales for Branded MRSA Products by Company, 2014 and 2024
  • Figure 6: Company Portfolio Gap Analysis in MRSA, 2014-2024
Back to Top